Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

NCT ID: NCT00517933

Last Updated: 2015-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2009-10-31

Brief Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.

Detailed Description

IPF is a disease in which fibrous tissue clogs the lungs. This eventually damages air sacs in the lungs and leads to widespread and permanent scarring of lung tissue. Individuals with IPF may experience breathing difficulties, cough, chest pain, and a decreased exercise capacity. Pulmonary hypertension, which is high blood pressure in the arteries of the lungs, affects half of all people with IPF. The fibrous tissue that clogs the lungs also blocks blood from flowing through the lungs effectively, reducing the amount of oxygen in the lungs. The fibrous tissue also reduces the lungs' ability to use what oxygen is available. These factors can cause breathing difficulties and may eventually lead to heart disease. Sildenafil is a medication that can increase blood supply to the lungs and reduce the heart's workload. The purpose of this study is to evaluate the effectiveness of sildenafil at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.

This study will enroll people with advanced IPF. Participants will be randomly assigned to receive sildenafil or placebo three times a day for 12 weeks. Study visits will occur at baseline and Weeks 1, 6, and 12. At Week 12, participants will have the option to continue in the study for an additional 12 weeks. All participants who agree to continue in the study will receive sildenafil three times a day for the second 12 weeks. Study visits will occur at Weeks 13, 18, and 24. At all study visits, a physical exam and blood collection will occur. At selected visits, the following study procedures will occur: lung function testing; urine collection; a 6-minute walk test, which will measure the distance walked in a 6-minute period; and questionnaires to assess health status, breathing, and quality of life. Participants will record medication usage and symptoms in a daily diary. Study researchers will review medical records and the Social Security death index 5 years following the end of the study to determine the incidence of death among study participants.

Conditions

Pulmonary Fibrosis; Hypertension, Pulmonary

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Sildenafil

20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks

Group Type: ACTIVE_COMPARATOR

Sildenafil Citrate

Intervention Type: DRUG

Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)

Placebo / Sildanafil

20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)

Interventions

Sildenafil Citrate

Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)

Intervention Type: DRUG

Placebo

Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)

Intervention Type: OTHER

Other Intervention Names

Revatio

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of IPF
• Diffusing capacity of the lung (DLCO) level less than 35% (adjusted for hemoglobin)

Exclusion Criteria

• Current enrollment in another investigational study
• Six-minute walk distance of less than 50 meters at screening or study entry
• Difference of greater than 15% between the screening and study entry 6-minute walk distance
• Acute or long-term impairment other than dyspnea (e.g., angina pectoris, intermittent claudication) that limits the ability to comply with the 6-minute walk test or other study requirements
• Forced Expiratory Volume 1-second (FEV1)/forced vital capacity (FVC) ratio of less than 0.65 after bronchodilator use
• Extent of emphysema greater than the extent of fibrotic change (e.g., honeycombing, reticular changes) on high-resolution computed tomography (HRCT) scan
• Acute heart attack within the 6 months prior to study entry
• Nitrate use
• Hypersensitivity to sildenafil or any component of the formulation
• Presence of aortic stenosis (AS)
• Life-threatening arrhythmia within 1 month of study entry
• Diabetes mellitus requiring insulin therapy
• Second-degree or third-degree atrioventricular (AV) block on electrocardiogram
• Severe chronic heart failure, defined by left ventricular ejection fraction (LVEF) of less than 25%
• Presence of idiopathic hypertrophic subaortic stenosis (IHSS)
• Hypotension (i.e., systolic blood pressure [SBP] less than 100 mm Hg or diastolic blood pressure [DBP] less than 50 mm Hg)
• Uncontrolled systemic hypertension (i.e., SBP greater than 180 mm Hg or DBP greater than 100 mm Hg)
• Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma, leukemia) that may predispose participant to priapism
• Aspartate aminotransferase (AST), serum glutamic pyruvic transaminase (SGPT), alanine aminotransferase (ALT), or serum glutamic oxaloacetic transaminase (SGOT) greater than three times the upper limit of normal range
• Kidney impairment (i.e., creatinine clearance less than 30 mL/minute)
• Current drug or alcohol dependence
• Retinitis pigmentosa
• History of vision loss
• History of nonarteritic ischemic optic neuropathy
• Recently initiated pulmonary rehabilitation within 30 days of study entry. Participants will be prohibited from starting pulmonary rehabilitation during the study. Participants who are currently undergoing maintenance pulmonary rehabilitation at study entry will be asked to maintain their levels of rehabilitation for the duration of the study.
• Use of any investigational therapy as part of a clinical trial for any medical condition within 30 days of study entry
• Start or change in dose of treatment for IPF investigational agent (e.g., interferon gamma-1b, pirfenidone, etanercept, N-acetylcysteine, any other investigational agent intended to treat IPF), corticosteroids, or cytotoxic agents within 30 days of study entry
• Use of certain medications. More information about this criterion can be found in the study protocol.
• Treatment for pulmonary hypertension with prostaglandins (e.g., epoprostenol, treprostinil), endothelin-1 antagonists (e.g., bosentan, sitaxsentan, ambrisentan), or any other phosphodiesterase inhibitor (e.g., tadalafil, vardenafil) within 30 days of study entry
• Addition or discontinuation of calcium channel blockers, digitalis, diuretics, or vasodilators within 30 days of study entry (dosage must be stable for 7 days prior to study entry [except for diuretics])
• Currently on the waiting list for a lung transplant
• Use of L-arginine supplements
• Use of grapefruit juice or St. John's wort
• Pregnant or breastfeeding
• Resting saturation of peripheral oxygen (SpO2) (i.e., oxygen saturation measured using pulse oximetry) less than 92% with 6 liters of supplemental oxygen

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Pfizer

INDUSTRY

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gary Hunninghake, MD

Role: STUDY_CHAIR

University of Iowa

Kevin Brown, MD

Role: PRINCIPAL_INVESTIGATOR

National Jewish Health

Rob Kaner, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College at Cornell University

Talmadge King, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Joe Lasky, MD

Role: PRINCIPAL_INVESTIGATOR

Tulane University

James Loyd, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University

Fernando Martinez, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Imre Noth, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Ganesh Raghu, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Jesse Roman, MD

Role: PRINCIPAL_INVESTIGATOR

Emory University

Jay Ryu, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

David Zisman, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Kevin Anstrom, PhD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Herbert Reynolds, MD

Role: STUDY_DIRECTOR

National Heart, Lung, and Blood Institute (NHLBI)

Lake D Morrison, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

University of Alabama - Birmingham

Birmingham, Alabama, United States

University of California - Los Angeles

Los Angeles, California, United States

University of California - San Francisco

San Francisco, California, United States

National Jewish Medical and Research Center

Denver, Colorado, United States

Emory University

Atlanta, Georgia, United States

University of Chicago

Chicago, Illinois, United States

Tulane University

New Orleans, Louisiana, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Weill Medical College of Cornell University

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Vanderbilt University

Nashville, Tennessee, United States

University of Washington

Seattle, Washington, United States

Countries

United States

References

Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, Kaner RJ; IPFnet Investigators. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest. 2015 Oct;148(4):1034-1042. doi: 10.1378/chest.14-2889.

Reference Type: DERIVED

PMID: 26111071 (View on PubMed)

Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ; IPFnet investigators. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015 May;3(5):388-96. doi: 10.1016/S2213-2600(15)00093-4. Epub 2015 Apr 15.

Reference Type: DERIVED

PMID: 25890798 (View on PubMed)

Idiopathic Pulmonary Fibrosis Clinical Research Network; Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010 Aug 12;363(7):620-8. doi: 10.1056/NEJMoa1002110. Epub 2010 May 18.

Reference Type: DERIVED

PMID: 20484178 (View on PubMed)

Related Links

http://www.ipfnet.org

Click here for the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) Web site

Other Identifiers

U10HL080413

Identifier Type: NIH

Identifier Source: secondary_id

View Link

507

Identifier Type: -

Identifier Source: secondary_id

Pro00018538

Identifier Type: -

Identifier Source: org_study_id